Integrin alpha V beta 5

Integrin alpha V beta 5

Integrin alpha V beta 5 Molekülinformation

Molecule Name
Integrin alpha-V/beta-5
Molekülalias
Integrin alpha V beta 5,ITGAV&ITGB5
Drug Development Progress
Anzahl der klinischen Arzneimittel3
Anzahl der inverkehr gebrachten Arzneimittel0
Höchste Forschungs- und EntwicklungsphasePhase 1 Clinical
Target-Alias
Receptors, Vitronectin
Molekülhintergrund
Integrin alpha V beta 5 (ITGAV & ITGB5) is expressed on a wide variety of cell types including keratinocytes, fibroblasts, adhesive monocytes, embryonic stem cells, and select endothelium and epithelium. ITGAV & ITGB5 binds ligands containing an RGD motif, notably vitronectin. Growth factors that increase PKC activity, such as VEGF or TGF alpha, promote ITGAV & ITGB5-mediated angiogenesis while alpha V beta 3, which may be expressed in the same cell, responds to FGF-basic and TNF alpha. An inhibitor of both down regulates tumor angiogenesis. During lung inflammation, up regulation of ITGAV & ITGB5 on myofibroblasts or infiltrating lymphocytes may contribute to fibrosis by freeing TGF beta from latency.

Integrin alpha V beta 5 Produktliste

No Data
You Have Viewed 0 Of 0 Results
  • 1

Can’t find what you need?

Submit your requirements and our technical
team will help.

Klinische Arzneimittelinformation

Englischer NameForschungscodeForschungsphaseFirmaIndikationenKlinische Studie
RisuteganibALG-1001; AM011; AM-011(Allegro Ophthalmics)Phase 1 ClinicalAllegro Ophthalmics Llc
Diabetic macular oedema; Diabetic Retinopathy; Geographic Atrophy; Macular Degeneration
Details
177Lu-FF-10158177Lu-FF-10158Phase 1 ClinicalFujifilm Holdings Corp
Glioblastoma
Details
NP-011NP-011Phase 1 ClinicalNexell Therapeutics Inc
Myocardial Infarction
Details